Hill Packaging

With more than 50 years of experience, McPherson designs and manufactures a variety of instruments and systems for spectroscopy. Its products include spectrometers, monochromators, fluorescence detectors, test stations, penetration-welded components, and vacuum, digital scanning and sample handling systems. The company additionally provides sample chambers, filter wheels, reflective condensers, fiber optics, telescopes, collimators, isolation valves, pumping manifolds, wavelength drives, polarizer mounts and optical choppers. It offers data acquisition, calibration, thin film analysis, measurement, plane grating, engineering, quality control and vacuum leak testing services. The company also provides fabrication, assembling, technical support, shipping, labeling, machining, machining and replacement services. McPherson s clients include Abbott Laboratories, Fastmetrix, Transoptics, Applied Analytical Industries and the Arizona State University.

Located in Lynn, Mass., ERC Wiping Products Inc. is one of the leading processors and distributors of wiping rags, towels and spill control products to industry and service companies. Occupying a 75,000-square foot facility, it distributes various items, such as absorbent cotton wiping cloths, soft polishing cloths, low cost rags, terry towels, presaturated wipes and durable paper wipers. Operational for over 88 years, it provides the largest selection of terry towels. The company's equipment includes a pallet stretch wrap machine, fork trucks, automated box sealers, pallet jacks, and a label barcoding machine. ERC Wiping Products Inc. has affiliations with iHRSA, NEHRSA, Vacation Rental Housekeeping Professionals, Textile Rental Services Association of America (TRSA), Better Business Bureau (BBB), SMART, MassRecycle and International Carwash Association.

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website